VTAK Quote, Financials, Valuation and Earnings

InfuSystems Holdings has a net margin of -4291.67% compared to Catheter Precision's net margin of 2.76%. Catheter Precision's return on equity of -65.84% beat InfuSystems Holdings's return on equity of 4.33%.

Catheter Precision has a consensus price target of --, signalling upside risk potential of 473.07%. On the other hand InfuSystems Holdings has an analysts' consensus of $14.13 which suggests that it could grow by 163.53%. Given that Catheter Precision has higher upside potential than InfuSystems Holdings, analysts believe Catheter Precision is more attractive than InfuSystems Holdings.

Catheter Precision has a beta of -0.775, which suggesting that the stock is 177.508% less volatile than S&P 500. In comparison InfuSystems Holdings has a beta of 1.898, suggesting its more volatile than the S&P 500 by 89.81%.

Catheter Precision has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. InfuSystems Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Catheter Precision pays -- of its earnings as a dividend. InfuSystems Holdings pays out -- of its earnings as a dividend.

Catheter Precision quarterly revenues are $96K, which are smaller than InfuSystems Holdings quarterly revenues of $33.8M. Catheter Precision's net income of -$4.1M is lower than InfuSystems Holdings's net income of $933K. Notably, Catheter Precision's price-to-earnings ratio is 0.40x while InfuSystems Holdings's PE ratio is 53.60x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Catheter Precision is 0.93x versus 0.86x for InfuSystems Holdings. Usually stocks with elevated PS ratios are considered overvalued.

Retractable Technologies has a net margin of -4291.67% compared to Catheter Precision's net margin of -18.58%. Catheter Precision's return on equity of -65.84% beat Retractable Technologies's return on equity of -16.83%.

Catheter Precision has a consensus price target of --, signalling upside risk potential of 473.07%. On the other hand Retractable Technologies has an analysts' consensus of -- which suggests that it could fall by --. Given that Catheter Precision has higher upside potential than Retractable Technologies, analysts believe Catheter Precision is more attractive than Retractable Technologies.

Catheter Precision has a beta of -0.775, which suggesting that the stock is 177.508% less volatile than S&P 500. In comparison Retractable Technologies has a beta of 2.279, suggesting its more volatile than the S&P 500 by 127.852%.

Catheter Precision has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Retractable Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Catheter Precision pays -- of its earnings as a dividend. Retractable Technologies pays out -3.32% of its earnings as a dividend.

Catheter Precision quarterly revenues are $96K, which are smaller than Retractable Technologies quarterly revenues of $10.3M. Catheter Precision's net income of -$4.1M is lower than Retractable Technologies's net income of -$1.9M. Notably, Catheter Precision's price-to-earnings ratio is 0.40x while Retractable Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Catheter Precision is 0.93x versus 0.56x for Retractable Technologies. Usually stocks with elevated PS ratios are considered overvalued.

VolitionRX has a net margin of -4291.67% compared to Catheter Precision's net margin of -1226.82%. Catheter Precision's return on equity of -65.84% beat VolitionRX's return on equity of --.

Catheter Precision has a consensus price target of --, signalling upside risk potential of 473.07%. On the other hand VolitionRX has an analysts' consensus of $3.37 which suggests that it could grow by 550.47%. Given that VolitionRX has higher upside potential than Catheter Precision, analysts believe VolitionRX is more attractive than Catheter Precision.

Catheter Precision has a beta of -0.775, which suggesting that the stock is 177.508% less volatile than S&P 500. In comparison VolitionRX has a beta of 1.155, suggesting its more volatile than the S&P 500 by 15.463%.

Catheter Precision has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Catheter Precision pays -- of its earnings as a dividend. VolitionRX pays out -- of its earnings as a dividend.

Catheter Precision quarterly revenues are $96K, which are smaller than VolitionRX quarterly revenues of $474.5K. Catheter Precision's net income of -$4.1M is higher than VolitionRX's net income of -$5.8M. Notably, Catheter Precision's price-to-earnings ratio is 0.40x while VolitionRX's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Catheter Precision is 0.93x versus 33.47x for VolitionRX. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings has a net margin of -4291.67% compared to Catheter Precision's net margin of -10.04%. Catheter Precision's return on equity of -65.84% beat Xtant Medical Holdings's return on equity of -35.34%.

Catheter Precision has a consensus price target of --, signalling upside risk potential of 473.07%. On the other hand Xtant Medical Holdings has an analysts' consensus of $1.75 which suggests that it could grow by 272.26%. Given that Catheter Precision has higher upside potential than Xtant Medical Holdings, analysts believe Catheter Precision is more attractive than Xtant Medical Holdings.

Catheter Precision has a beta of -0.775, which suggesting that the stock is 177.508% less volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of -0.033, suggesting its less volatile than the S&P 500 by 103.341%.

Catheter Precision has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Catheter Precision pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

Catheter Precision quarterly revenues are $96K, which are smaller than Xtant Medical Holdings quarterly revenues of $31.5M. Catheter Precision's net income of -$4.1M is lower than Xtant Medical Holdings's net income of -$3.2M. Notably, Catheter Precision's price-to-earnings ratio is 0.40x while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Catheter Precision is 0.93x versus 0.54x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.